Toxicologic properties of 2′-o-methoxyethyl chimeric antisense inhibitors in animals and man

Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition

Volumn , Issue , 2007, Pages 327-363

  Henry, Scott P ^a   Kim, Tae Won ^a   Kramer Stickland, Kimberly ^b   Zanardi, Thomas A ^a   Fey, Robert A ^a   Levin, Arthur A ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904872039     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (126)

1. Crooke, S. T., Antisense Drug Technology: Basic Principles, Strategies, and Applications, Marcel Dekker, New York, 2001.
2. Zinker, B. A., Rondinone, C. M., Trevillyan, J. M., Gum, R. J., Clampit, J. E., Waring, J. F., Xie, N., Wilcox, D., Jacobson, P., Frost, L., Kroeger, P. E., Reilly, R. M., Koterski, S., Opgenorth, T. J., Ulrich, R. G., Crosby, S., Butler, M., Murray, S. F., McKay, R. A., Bhanot, S., Monia, B. P., and Jirousek, M. R., PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice, Proc. Natl. Acad. Sci. USA 99(17), 11,357, 2002.
3. Butler, M., McKay, R. A., Popoff, I. J., Gaarde, W. A., Witchell, D., Murray, S. F., Dean, N. M., Bhanot, S., and Monia, B. P., Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice, Diabetes 51(4), 1028, 2002.
4. Crooke, R. M., Graham, M. J., Lemonidis, K. M., Whipple, C. P., Koo, S., and Perera, R. J., An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis, J. Lipid Res. 46(5), 872, 2005.
5. Chi, K. N., Eisenhauer, E., Fazli, L., Jones, E. C., Goldenberg, S. L., Powers, J., and Gleave, M. E., A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′methoxyethyl antisense to clusterin, in patients with localized prostate cancer prior to radical prostatectomy, 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, 2004.
6. Kastelein, J. J. P., Wedel, M. K., Baker, B. F., Su, J., Bradley, J. D., Yu, R. Z., Chuang, E., Graham, M. J., and Crooke, R. M., Potent reduction of apolipoprotein B and LDL cholesterol by an antisense inhibitor of apolipoprotein B, Circulation, in press.
7. Moore, J., Seiter, K., Kolitz, J., Stock, W., Giles, F., Kalaycio, M., Zenk, D., and Marcucci, G., A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse, Leuk. Res. 30(7), 777, 2006.
8. O’Brien, S. M., Cunningham, C. C., Golenkov, A. K., Turkina, A. G., Novick, S. C., and Rai, K. R., Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia, J. Clin. Oncol. 23(30), 7697, 2005.
9. Miner, P. B., Jr., Geary, R. S., Matson, J., Chuang, E., Xia, S., Baker, B. F., and Wedel, M. K., Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis, Aliment. Pharmacol. Ther. 23(10), 1427, 2006.
10. Levin, A. A., Henry, S. P., Monteith, D., and Templin, M., Toxicity of antisense oligonucleotides, in Antisense Drug Technology, Crooke, S. T., ed., Marcel Dekker, New York, 2001, p. 201.
11. Geary, R. S., Yu, R. Z., Watanabe, T., Henry, S. P., Hardee, G. E., Chappell, A., Matson, J., Sasmor, H., Cummins, L., and Levin, A. A., Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species, Drug Metab. Dispos., 31(11), 1419, 2003.
12. Henry, S. P., Geary, R. S., Yu, R., and Levin, A. A., Drug properties of second-generation antisense oligonucleotides:how do they measure up to their predecessors? Curr. Opin. Investig. Drugs 2(10), 1444, 2001.
13. Monia, B. P., Johnston, J. F., Sasmor, H., and Cummins, L. L., Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras, J. Biol. Chem. 271(24), 14,533, 1996.
14. Altmann, K.-H., Dean, N. M., Fabbro, D., Freier, S. M., Geiger, T., Haner, R., Husken, D., Martin, P., Monia, B. P., Muller, M., Natt, F., Nicklin, P., Phillips, J., Pieles, U., Sasmor, H., and Moser, H., E., Second generation of antisense oligonucleotides: from nuclease resistance to biological efficacy in animals, Chimia 50(4), 168, 1996.
15. Cummins, L. L., Owens, S. R., Risen, L. M., Lesnik, E. A., Freier, S. M., McGee, D., Guinosso, C., J., and Cook, P. D., Characterization of fully 2′-modified oligoribonucleotide hetero-and homoduplex hybridization and nuclease sensitivity, Nucleic Acids Res. 23(11), 2019, 1995.
16. Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., and Freier, S. M., Evaluation of 2′ modified oligonucleotides containing deoxy gaps as antisense inhibitors of gene expression, J. Biol. Chem. 268, 14,514, 1993.
17. Cheng, A. J., Wang, J. C., and Van Dyke, M. W., Self-association of G-rich oligodeoxyribonucleotides under conditions promoting purine-motif triplex formation, Antisense Nucleic Acid Drug Dev. 8(3), 215, 1998.
18. Krieg, A. M., CpG motifs in bacterial DNA and their immune effects, Annu. Rev. Immunol. 20, 709, 2002.
19. Krieg, A. M., CpG DNA: a novel immunomodulator, Trends Microbiol. 7(2), 64, 1999.
20. Yu, R. Z., Riley, G., Hoc, K., Watanabe, T. A., Matson, J., Murray, S., Booten, S., Bhanot, S., Monia, B., and Geary, R. S., Effect of treatment regimen on sub-organ pharmacodynamics of a 2′-MOE modified antisense oligonucleotide, Isis 116847, targeting putative protein tyrosine phosphatase(PTEN) mRNA in rats, in AAPS Annual Meeting and Exposition, American Association of Pharmaceutical Scientists, Salt Lake City, UT, 2003.
21. Black, L. E., DeGeorge, J. J., Cavagnaro, J. A., Jordan, A., and Ahn, C.-H., Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs, Antisense Res. Dev. 3, 399, 1993.
22. Black, L. E., Farrelly, J. G., Cavagnaro, J. A., Ahn, C.-H., DeGeorge, J. J., Taylor, A. S., DeFelice, A. F., and Jordan, A., Regulatory considerations of oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies, Antisense Res. Dev. 4, 299, 1994.
23. Ahn, C.-H. and DeGeorge, J. J., Preclinical development of antisense oligonucleotide therapeutics for cancer: regulatory aspects, in Clinical Trials of Genetic Therapy with Antisense DNA and DNA Vectors, Wickstrom, E. ed., Marcel Dekker, New York, NY, 1998, p. 39.
24. Henry, S. P., Geary, R. S., Yu, R., Templin, M. V., Pallman, J., and Levin, A. A., Comparison of toxicity and tissue concentrations for 1st and 2nd generation antisense oligonucleotide, The Toxicologist 60, 325, 2001.
25. Watanabe, T. A., Geary, R. S., and Levin, A. A., In vitro protein binding and drug interaction studies of an antisense oligonucleotide (ASO), Isis 113715, targeting human Ptb1b mRNA, AAPS Annual Meeting and Exposition, American Association of Pharmaceutical Scientists, Baltimore MD, 2004.
26. Geary, R. S., Ushiro-Watanabe, T., Truong, L., Freier, S. M., Lesnik, E. A., Sioufi, N. B., Sasmor, H., Manoharan, M., and Levin, A. A., Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats, J. Pharmacol. Exp. Ther. 296(3), 890, 2001.
27. Watanabe, T., Geary, R. S., and Levin, A. A., Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302), Oligonucleotides, 16, 169-180, 2006.
28. Agrawal, S. and Temsamani, J., Comparative pharmacokinetics of antisense oligonucleotides, in Antisense Therapeutics, Agrawal, S., ed., Humana Press, Totowa, NJ, 1996, p. 247.
29. Crooke, S. T., Proof of mechanism of antisense drugs, Antisense Nucleic Acid Drug Dev. 6(2), 145, 1996.
30. Yu, R. Y., McArdle, E. J., Riley, G., Hoc, K., Nishihara, K. C., Watanabe, T. A., Pandey, S. K., Bhanot, S., and Geary, R. S., In vivo pharmacodynamics and sub-cellular distribution of a 2′-MOE modified antisense oligonucleotide (ASO), ISIS 116847, targeting putative protein tyrosine phosphatase (PTEN) mRNA in mice and rats, Annual Meeting of the Society of Toxicology and Chemistry, Baltimore, Maryland, 2002.
31. Yu, R. Z., Zhang, H., Geary, R. S., Graham, M., Masarjian, L., Lemonidis, K., Crooke, R., Dean, N. M., and Levin, A. A., Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice, J. Pharmacol. Exp. Ther. 296(2), 388, 2001.
32. Henry, S. P., Grillone, L. R., Orr, J. L., Brunner, R. H., and Kornbrust, D. J., Comparison of the toxicity profiles of ISIS 1082 and ISIS 2105, phosphorothioate oligonucleotides, following subacute intradermal administration in Sprague-Dawley rats, Toxicology 116, 77, 1997.
33. Nyce, J. W. and Metzger, W. J., DNA antisense therapy for asthma in an animal model, Nature 385(6618), 721, 1997.
34. Allakhverdi, Z., Allam, M., and Renzi, P. M., Inhibition of antigen-induced eosinophilia and airway hyperresponsiveness by antisense oligonucleotides directed against the common beta chain of IL-3, IL-5, GM-CSF receptors in a rat model of allergic asthma, Am. J. Respir. Crit. Care Med. 165(7), 1015, 2002.
35. Templin, M. V., Levin, A. A., Graham, M. J., Aberg, P. M., Axelsson, B. I., Butler, M., Geary, R. S., and Bennett, C. F., Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice, Antisense Nucleic Acid Drug Dev. 10(5), 359, 2000.
36. Ali, S., Leonard, S. A., Kukoly, C. A., Metzger, W. J., Wooles, W. R., McGinty, J. F., Tanaka, M., Sandrasagra, A., and Nyce, J. W., Absorption, distribution, metabolism, and excretion of a respirable antisense oligonucleotide for asthma, Am. J. Respir. Crit. Care Med. 163(4), 989, 2001.
37. Duan, W., Chan, J. H., McKay, K., Crosby, J. R., Choo, H. H., Leung, B. P., Karras, J. G., and Wong, W. S., Inhaled p38 alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice, Am. J. Respir. Crit. Care Med. 171(6), 571, 2005.
38. Agrawal, S., Jiang, Z., Zhao, Q., Shaw, D., Cai, Q., Roskey, A., Channavajjala, L., Saxinger, C., and Zhang, R., Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies, Proc. Natl. Acad. Sci. USA 94(6), 2620, 1997.
39. Geary, R. S., Mathison, B., Ushiro-Watanabe, T., Savides, M. C., Henry, S. P., and Levin, A. A., Second generation antisense oligonucleotide pharmacokinetics and mass balance following intravenous administration in rats, The Toxicologist, Oxford University Press, San Francisco, CA, 2001, p. 343.
40. Jaeger, L. B. and Banks, W. A., Antisense therapeutics and the treatment of CNS disease, Front. Biosci. 9, 1720, 2004.
41. Godfray, J. and Estibeiro, P., The potential of antisense as a CNS therapeutic, Expert Opin. Ther. Targets 7(3), 363, 2003.
42. Anderberg, E. K., Lindmark, T., and Artursson, P., Sodium caprate elicits dilatations in human intestinal tight junctions and enhances drug absorption by the paracellular route, Pharm. Res. 10(6), 857, 1993.
43. Senn, J. J., Burel, S., and Henry, S. P., Non-CpG containing antisense 2′ MOE oligonucleotides activate a proinflammatory response independent of TLR-9 or MyD88, J. Pharmacol. Exp. Ther. 314, 972, 2005.
44. Yu, R. Z., Geary, R. S., Ushiro-Watanabe, T., Levin, A. A., and Schoenfeld, S. L., Pharmacokinetic properties in humans, in Antisense Drug Technology: Principles, Strategies, and Applications, Crooke, S. T., ed., Marcel Dekker, New York, 2001, p. 183.
45. DeGeorge, J. J., Ahn, C.-H., Andrews, P. A., Brower, M. E., Giorgio, D. W., Goheer, M. A., Doo, L.-H. Y., McGuinn, W. D., Schmidt, W., Sun, C. J., and Tripathi, S. C., Regulatory considerations for preclinical development of anticancer drugs, Cancer Chemother. Pharmacol. 41(3), 173, 1997.
46. Yacyshyn, B. R., Chey, W. Y., Goff, J., Salzberg, B., Baerg, R., Buchman, A. L., Tami, J., Yu, R., Gibiansky, E., and Shanahan, W. R., Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn’s disease, Gut 51(1), 30, 2002.
47. Yacyshyn, B., Bowen-Yacyshyn, M. B., and Shanahan, W., The clinical experience of antisense therapy to ICAM-1 in Crohn’s disease, Curr. Opin. Mol. Ther. 1(3), 332, 1999.
48. Sewell, L. K., Geary, R. S., Baker, B. F., Glover, J. M., Mant, T. G. K., Yu, R. Z., Tami, J. A., and Dorr, A. F., Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha, J. Pharmacol. Exp. Ther. 303(3), 1334, 2002.
49. Henry, S. P., Novotny, W., Leeds, J., Auletta, C., and Kornbrust, D. J., Inhibition of coagulation by a phosphorothioate oligonucleotide, Antisense Nucleic Acid Drug Dev. 7, 503, 1997.
50. Sheehan, J. P. and Lan, H.-C., Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex, Blood 92(5), 1617, 1998.
51. Sheehan, J. P. and Thao, P. M., Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism, Biochemistry 40(16), 4980, 2001.
52. Henry, S. P., Bolte, H., Auletta, C., and Kornbrust, D. J., Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys, Toxicology 120, 145, 1997.
53. Jeter, M. L., Ly, L. V., Fortenberry, Y. M., Whinna, H. C., White, R. R., Rusconi, C. P., Sullenger, B. A., and Church, F. C., RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins, FEBS Lett. 568(1-3), 10, 2004.
54. Paborsky, L. R., McCurdy, S. N., Griffin, L. C., Toole, J. J., and Leung, L. L., The single-stranded DNA aptamer-binding site of human thrombin, J. Biol. Chem. 268(28), 20,808, 1993.
55. Henry, S. P., Beattie, G., Yeh, G., Chappel, A., Giclas, P. C., Mortari, A., Jagels, M. A., Kornbrust, D. J., and Levin, A. A., Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide, Int. J. Immunopharmacol. 2(12), 1657, 2002.
56. Henry, S. P., Giclas, P. C., Leeds, J., Pangburn, M., Auletta, C., Levin, A. A., and Kornbrust, D. J., Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action, J. Pharmacol. Exp. Ther. 281(2), 810, 1997.
57. Oberbauer, R., Schreiner, G. F., and Meyer, T. W., Renal uptake of an 18-mer phosphorothioate oligonucleotide, Kidney Int. 48, 1226, 1995.
58. Rappaport, J., Hanss, B., Kopp, J. B., Copeland, T. D., Bruggeman, L. A., Coffman, T. M., and Klotman, P. E., Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy, Kidney Int. 47, 1462, 1995.
59. Butler, M., Stecker, K., and Bennett, C. F., Histological localization of phosphorothioate oligodeoxynucleotides in normal rodent tissue, Nucleos. Nucleot. 16(7-9), 1761, 1997.
60. Monteith, D. K., Geary, R. S., Leeds, J. M., Johnston, J., Monia, B. P., and Levin, A. A., Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys, Toxicol. Sci. 46(2), 365, 1998.
61. Monteith, D. K., Horner, M. J., Gillett, N. A., Butler, M., Geary, R. S., Burckin, T., Ushiro-Watanabe, T., and Levin, A. A., Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys, Toxicol. Pathol. 27(3), 307, 1999.
62. Henry, S. P., Johnson, M., Zanardi, T. A., Fey, R., Auyeung, D., Lappin, P. B., and Levin, A. A., Renal uptake and tolerability of a 2′-O-methoxyethyl modified antisense oligonucleotide (ISIS 113715) in monkey, Toxicol. Sci., submitted.
63. Bendele, A., Seely, J., Richey, C., Sennello, G., and Shopp, G., Short communication: renal tubular vacuolation in animals treated with polyethylene-glycol-conjugated proteins, Toxicol. Sci. 42(2), 152, 1998.
64. Conover, C. D., Linberg, R., Gilbert, C. W., Shum, K. L., and Shorr, R. G., Effect of polyethylene glycol conjugated bovine hemoglobin in both top-load and exchange transfusion rat models, Artif. Organs 21(10), 1066, 1997.
65. Merski, J. A. and Meyers, M. C., Light-and electron-microscopic evaluation of renal tubular cell vacuolation induced by administration of nitrilotriacetate or sucrose, Food Chem. Toxicol. 23(10), 923, 1985.
66. Kone, B. C., Racusen, L. C., Whelton, A., and Solez, K., Acute renal failure produced by combining cyclosporine and brief renal ischemia in the Munich Wistar rat, Clin. Nephrol. 25, Suppl. 1, S171, 1986.
67. Kintzel, P. E., Anticancer drug-induced kidney disorders, Drug Safety 24(1), 19, 2001.
68. El-Badawi, M. G., Abdalla, M. A., Bahakim, H. M., and Fadel, R. A., Nephrotoxicity of low-dose methotrexate in guinea pigs: an ultrastructural study, Nephron 73(3), 462, 1996.
69. Guillermina, G., Adriana, T. M., and Monica, E. M., The implication of renal glutathione levels in mercuric chloride nephrotoxicity, Toxicology 58(2), 187, 1989.
70. Agrawal, S., Temsamani, J., Galbraith, W., and Tang, J., Pharmacokinetics of antisense oligonucleotides, Clin. Pharmacokinet. 28(1), 7, 1995.
71. Graham, M. J., Crooke, S. T., Monteith, D. K., Cooper, S. R., Lemonidis, K. M., Stecker, K. K., Martin, M. J., and Crooke, R. M., In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration, J. Pharmacol. Exp. Ther. 286(1), 447, 1998.
72. Ponnappa, B. C. and Israel, Y., Targeting Kupffer cells with antisense oligonucleotides, Front. Biosci. 7, e223, 2002.
73. Ponnappa, B. C., Israel, Y., Aini, M., Zhou, F., Russ, R., Cao, Q. N., Hu, Y., and Rubin, R., Inhibition of tumor necrosis factor alpha secretion and prevention of liver injury in ethanol-fed rats by antisense oligonucleotides, Biochem. Pharmacol. 69(4), 569, 2005.
74. Henry, S. P., Stecker, K., Brooks, D., Monteith, D., Conklin, B., and Bennett, C. F., Chemically modified oligonucleotides exhibit decreased immune stimulation in mice, J. Pharmacol. Exp. Ther. 292(2), 468, 2000.
75. Zhao, Q., Temsamani, J., Iadarola, P. L., Jiang, Z., and Agrawal, S., Effect of different chemically modified oligodeoxynucleotides on immune stimulation, Biochem. Pharmacol. 51(2), 173, 1996.
76. Schechter, P. J. and Martin, R. R., Safety and tolerance of phosphorothioates in humans, in Antisense Research and Applications, Crooke, S. T., ed., Springer-Verlag, Berlin, Heidelberg, 1998, p. 231.
77. Glover, J. M., Leeds, J. M., Mant, T. G., Amin, D., Kisner, D. L., Zuckerman, J. E., Geary, R. S., Levin, A. A., and Shanahan, W. R., Jr., Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302), J. Pharmacol. Exp. Ther. 282(3), 1173, 1997.
78. Levine, A. M., Tulpule, A., Quinn, D. I., Gorospe, G., 3rd, Smith, D. L., Hornor, L., Boswell, W. D., Espina, B. M., Groshen, S. G., Masood, R., and Gill, P. S., Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy, J. Clin. Oncol. 24(11), 1712, 2006.
79. Holmlund, J. T., Monia, B. P., Kwoh, J. T., and Dorr, A. F., Towards antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development, Curr. Opin. Mol. Ther. 1(3), 372, 1999.
80. Dorr, F. A., Clinical development of phosphorothioate (P=S) antisense oligodeoxynucleotide inhibitors of PKC-a mRNA (Isis 3521, CGP 64128A) and C-raf kinase (Isis 5132, CGP 69846A), in XIIIth International Congress of Pharmacology, Munich, Germany, 1998, p. R205.
81. Semple, J. W., Milev, Y., Cosgrave, D., Mody, M., Hornstein, A., Blanchette, V., and Freedman, J., Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura:relationship to platelet phenotype and antiplatelet T-cell reactivity, Blood 87(10), 4245, 1996.
82. Krieg, A. M., The role of CpG motifs in innate immunity, Curr. Opin. Immunol. 12(1), 35, 2000.
83. Klinman, D. M., Takeshita, F., Gursel, I., Leifer, C., Ishii, K. J., Verthelyi, D., and Gursel, M., CpG DNA: recognition by and activation of monocytes, Microbes Infect. 4(9), 897, 2002.
84. Hartmann, G., Weiner, G. J., and Krieg, A. M., CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells, Proc. Natl. Acad. Sci. USA 96, 9305, 1999.
85. Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., and Klinman, D. M., CpG motifs in bacterial DNA trigger direct B-cell activation, Nature 374, 546, 1995.
86. Agrawal, S., Zhao, Q., Jiang, Z., Oliver, C., Giles, H., Heath, J., and Serota, D., Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats, Antisense Nucleic Acid Drug Dev. 7, 575, 1997.
87. Branda, R. F., Moore, A. L., Mathews, L., McCormack, J. J., and Zon, G., Immune stimulation by an antisense oligomer complimentary to the rev gene of HIV-1, Biochem. Pharmacol. 45(10), 2037, 1993.
88. Sarmiento, U. M., Perez, J. R., Becker, J. M., and Ramaswamy, N., In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice, Antisense Res. Dev. 4(2), 99, 1994.
89. Ballas, Z. K., Rasmussen, W. L., and Krieg, A. M., Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA, J. Immunol. 157(5), 1840, 1996.
90. Krieg, A. M. and Stein, C. A., Phosphorothioate oligodeoxynucleotides: Antisense or anti-protein? Antisense Res. Dev. 5(4), 241, 1995.
91. Stein, C. A., Phosphorothioate antisense oligodeoxynucleotides: questions of specificity, Tibtech 14, 147, 1996.
92. Vollmer, J., Jepsen, J. S., Uhlmann, E., Schetter, C., Jurk, M., Wader, T., Wullner, M., and Krieg, A. M., Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA), Oligonucleotides 14(1), 23, 2004.
93. Branda, R. F., Moore, A. L., Lafayette, A. R., Mathews, L., Hong, R., Zon, G., Brown, T., and McCormack, J. J., Amplification of antibody production by phosphorothioate oligodeoxynucleotides, J. Lab Clin. Med. 128(3), 329, 1996.
94. McIntyre, K. W., Lombard-Gilloly, K., Perez, J. R., Kunsch, C., Sarmiento, U. M., Larigan, J. D., Landreth, K. T., and Narayanan, R., A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-κB p65 causes sequence-specific immune stimulation, Antisense Res. Dev. 3, 309, 1993.
95. Liang, H., Nishioka, Y., Reich, C. F., Pisetsky, D. S., and Lipsky, P. E., Activation of human B cells by phosphorothioate oligodeoxynucleotides, J. Clin. Invest. 98(5), 1119, 1996.
96. Klinman, D. M., AE-Kyung, Y., Beaucage, S. L., Conover, J., and Krieg, A. M., CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ, Proc. Natl. Acad. Sci. USA 93, 2879, 1996.
97. Zhang, Y., Shoda, L. K., Brayton, K. A., Estes, D. M., Palmer, G. H., and Brown, W. C., Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide(ODN 2059) containing the GTCGTT motif, J. Interferon Cytokine Res. 21(10), 871, 2001.
98. Takeshita, S., Takeshita, F., Haddad, D. E., Ishii, K. J., and Klinman, D. M., CpG oligodeoxynucleotides induce murine macrophages to up-regulate chemokine mRNA expression, Cell Immunol. 206(2), 101, 2000.
99. Kanda, H., Tateya, S., Tamori, Y., Kotani, K., Hiasa, K.-i., Kitazawa, R., Kitazawa, S., Miyachi, H., Maeda, S., Egashira, K., and Kasuga, M., MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity, J. Clin. Invest. 116(6), 1494, 2006.
100. Cotter, F. E., Antisense therapy for cancer, Eur. J. Cancer 1(2), 19, 2003.
101. Takeshita, F., Gursel, I., Ishii, K. J., Suzuki, K., Gursel, M., and Klinman, D. M., Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9, Semin. Immunol. 16(1), 17, 2004.
102. Takeshita, F., Leifer, C. A., Gursel, I., Ishii, K. J., Takeshita, S., Gursel, M., and Klinman, D. M., Cutting edge: Role of toll-like receptor 9 in CpG DNA-induced activation of human cells, J. Immunol. 167, 3555, 2001.
103. Hacker, H., Vabulas, R. M., Takeuchi, O., Hoshino, K., Akira, S., and Wagner, H., Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6, J. Exp. Med. 192(4), 595, 2000.
104. Aderem, A. and Ulevitch, R. J., Toll-like receptors in the induction of the innate immune response, Nature 406(6797), 782, 2000.
105. Tsuboi, N., Yoshikai, Y., Matsuo, S., Kikuchi, T., Iwami, K.-I., Nagai, Y., Takeuchi, O., Akira, S., and Matsuguchi, T., Roles of toll-like receptors in C-C chemokine production by renal tubular epithelial cells, J. Immunol. 169(4), 2026, 2002.
106. Hornung, V., Rothenfusser, S., Britsch, S., Krug, A., Jahrsdorfer, B., Giese, T., Endres, S., and Hartmann, G., Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides, J. Immunol. 168(9), 4531, 2002.
107. Ho, P. P., Fontoura, P., Ruiz, P. J., Steinman, L., and Garren, H., An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems, J. Immunol. 171(9), 4920, 2003.
108. Vollmer, J., Janosch, A., Laucht, M., Ballas, Z. K., Schetter, C., and Krieg, A. M., Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes, Antisense Nucleic Acid Drug Dev. 12(3), 165, 2002.
109. Elias, F., Flo, J., Lopez, R. A., Zorzopulos, J., Montaner, A., and Rodriguez, J. M., Strong cytosineguanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs, J. Immunol. 171(7), 3697, 2003.
110. Ashman, R. F., Goeken, J. A., Drahos, J., and Lenert, P., Sequence requirements for oligodeoxyribonucleotide inhibitory activity, Int. Immunol. 17(4), 411, 2005.
111. Roberts, T. L., Sweet, M. J., Hume, D. A., and Stacey, K. J., Cutting Edge: Species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides, J. Immunol. 174(2), 605, 2005.
112. Younis, H. S., Vickers, T., Levin, A. A., and Henry, S. P., CpG and non-CpG oligodeoxynucleotides induce differential proinflammatory gene expression profiles in liver and peripheral blood leukocytes in mice, J. Immunotoxicol. 3(2), 57, 2006.
113. Karikó, K., Ni, H., Capodici, J., Lamphier, M., and Weissman, D., mRNA is an endogenous ligand for Toll-like receptor 3, J. Biol. Chem. 279(13), 12,542, 2004.
114. Lund, J. M., Alexopoulou, L., Sato, A., Karow, M., Adams, N. C., Gale, N. W., Iwasaki, A., and Flavell, R. A., Recognition of single-stranded RNA viruses by Toll-like receptor 7, Proc. Natl. Acad. Sci. USA 101(15), 5598, 2004.
115. Verthelyi, D. and Klinman, D. M., Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates, Clin. Immunol. 109(1), 64, 2003.
116. Hartmann, G., Weeratna, R. D., Ballas, Z. K., Payette, P., Blackwell, S., Suparto, I., Rasmussen, W. L., Waldschmidt, M., Sajuthi, D., Purcell, R. H., Davis, H. L., and Krieg, A. M., Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo, J. Immunol. 164(3), 1617, 2000.
117. Verthelyi, D., Ishii, K. J., Gursel, M., Takeshita, F., and Klinman, D. K., Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs, J. Immunol. 166, 2372, 2001.
118. Henry, S. P., Denny, K. H., Templin, M. V., Yu, R. Z., and Levin, A. A., Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice, Birth Defects Res. B Dev. Reprod. Toxicol. 71(6), 359, 2004.
119. Henry, S. P., Denny, K. H., Templin, M. V., Yu, R. Z., and Levin, A. A., Effects of an antisense oligonucleotide inhibitor of human ICAM-1 on fetal development in rabbits, Birth Defects Res. B Dev. Reprod. Toxicol. 71(6), 368, 2004.
120. Soucy, N. V., Riley, J. P., Templin, M. V., Geary, R., de Peyster, A., and Levin, A. A., Maternal and fetal distribution of a phosphorothioate oligonucleotide in rats after intravenous infusion, Birth Defects Res. B Dev. Reprod. Toxicol. 77(1), 22, 2006.
121. Krishnan, L., Guilbert, L. J., Wegmann, T. G., Belosevic, M., and Mosmann, T. R., T helper 1 response against Leishmania major in pregnant C57BL/6 mice increases implantation failure and fetal resorptions, J. Immunol. 156(2), 653, 1996.
122. Clark, D. A., Lea, R. G., Podor, T., Daya, S., Banwatt, D., and Harley, C., Cytokines determining the success or failure of pregnancy, Ann. NY Acad. Sci. 626, 524, 1991.
123. Driver, S. E., Robinson, G. S., Flanagan, J., Shen, W., Smith, L. E. H., Thomas, D. W., and Roberts, P. C., Oligonucleotide-based inhibition of embryonic gene expression, Nat. Biotechnol. 17, 1184, 1999.
124. Henry, S. P., Monteith, D. K., Matson, J. E., Mathison, B. H., Loveday, K. S., Winegar, R. A., Lee, P. S., Riccio, E. S., Bakke, J. P., and Levin, A. A., Assessment of the genotoxic potential of ISIS 2302: a phosphorothioate oligodeoxynucleotide, Mutagenesis 17(3), 201, 2002.
125. Wang, G., Seidman, M. M., and Glazer, P. M., Mutagenesis in mammalian cells induced by triple helix formation and transcription-coupled repair, Science 271(5250), 802, 1996.
126. European Medicines Agency, Reflection Paper on the Assessment of the Genotoxic Potential of Antisense Oligonucleotides, 2005.